We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BLEOMYCIN ACCORD (Accord Healthcare Pty Ltd)
Product name
BLEOMYCIN ACCORD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
117 (255 working days)
Active ingredients
bleomycin sulfate
Registration type
New generic medicine
Indication
Bleomycin is indicated for palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms:
- Squamous cell carcinoma of the skin, head and neck and oesophagus (primary indication)
- Squamous cell carcinoma of the larynx, penis and uterine cervix
- Squamous cell carcinoma of the bronchus (response infrequent)
- Choriocarcinoma and embryonal cell carcinoma of the testis
- Advanced Hodgkin’s disease and other lymphomas
- Mycosis fungoides.